Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is positioned for strong fundamental growth because 3Q26 revenue of $340.5M and diluted EPS of $1.01 both beat Street expectations, while management reaffirmed 2026 revenue guidance of $1.1B-$1.2B, implying about 51% growth at the midpoint. Lifyorli is scaling quickly, with 3Q26 sales of $91.4M in its second full commercial quarter, over 2,300 patients treated, and more than 1,700 prescribers, while Korlym still grew 19% year over year to $249.1M despite generic competition. The positive CHMP opinion for relacorilant in ovarian cancer, combined with the resubmission path for Cushing’s syndrome and management’s view that current assumptions on AG pricing erosion are conservative, supports confidence in a durable multiyear earnings expansion.

Corcept Therapeutics is facing a more uncertain growth path because MFN pricing announced on May 12, 2025 complicates the launch economics for Europe and makes the non-US outlook for Lifyorli unclear. The company has not committed to a European launch strategy, and that uncertainty limits visible incremental revenue even though market potential may exist beyond the US. At the same time, diluted shares outstanding rise from 111,742 thousand to 165,049 thousand in the provided figures, signaling meaningful dilution that can weigh on per-share value and offset commercial progress.